EUVIMEDEUVIMED entdecken
Übersichtsarbeit

High‐Risk HPV Oncoproteins and PD‐1/PD‐L1 Interplay

Shuai Zhen

Journal of Medical Virology · 2025-05 · 97 (5)

DOI: 10.1002/jmv.70415 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medical Virology, online erschienen am 22.05.2025. Verfasst von Shuai Zhen. Beteiligte Einrichtung: Center for Translational Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, B7-H1 Antigen, Papillomavirus Infections, Oncogene Proteins, Viral. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 88 Literaturangaben. Gefördert von: This study was supported by grants from the National Natural Science Foundation of China (Grant nos. 81602295 to Shuai Zhen)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human papillomavirus (HPV) related cancers often arise from a background of chronic inflammation. Systemic treatment for advanced HPV‐related cancers has been disappointing due to their strong resistance to chemotherapy and even to tyrosine kinase inhibitors (TKIs). Recently, the use of immune checkpoint inhibitor (ICI) therapy has revolutionized the systemic treatment of advanced HPV‐related cancers. For the first time, clinical trials testing ICIs, anti‐CTLA‐4, and anti‐PD1/PDL1 reported a survival benefit in patients with sorafenib resistance. However, it took a long time to find the right combination regimen to use ICIs in combination with the antiangiogenic agent bevacizumab to substantially prolong overall survival (OS) of patients with advanced HPV‐related cancer after sorafenib. This review provides a comprehensive history of ICI therapy in HPV‐related cancer, up‐to‐date information on the latest ICI clinical trials, and discusses the recent development of novel ICIs that would potentially lead to a new checkpoint blockade therapy for advanced HPV‐related cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorB7-H1 AntigenPapillomavirus InfectionsOncogene Proteins, ViralNeoplasmsPapillomaviridaeHumansImmune Checkpoint InhibitorsClinical Trials as Topic

Stichwörter der Autor:innen

cellular Effectcombination therapy: disease controlhuman papillomavirus: virus classification

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanPDCD1 protein, humanOncogene Proteins, Viral

Autor:innen und Institutionen

  • Center for Translational Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.
  • Genetic Disease Diagnosis Center of Shaanxi Province, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.

Förderung

  • This study was supported by grants from the National Natural Science Foundation of China (Grant nos. 81602295 to Shuai Zhen).

Zitieren

APA

Zhen, S. (2025). High‐Risk HPV Oncoproteins and PD‐1/PD‐L1 Interplay. Journal of Medical Virology, 97(5). https://doi.org/10.1002/jmv.70415

Vancouver

Zhen S. High‐Risk HPV Oncoproteins and PD‐1/PD‐L1 Interplay. Journal of Medical Virology. 2025;97(5). doi:10.1002/jmv.70415

BibTeX
@article{Zhen2025,
  author = {Zhen, Shuai},
  title = {High‐Risk HPV Oncoproteins and PD‐1/PD‐L1 Interplay},
  journal = {Journal of Medical Virology},
  year = {2025},
  volume = {97},
  number = {5},
  doi = {10.1002/jmv.70415}
}
Kostenlos starten →